|
Construction of a modified Arrhenius equation for predicting drug nitrosation in solid dosage form -Pub
|
|
2
|
561
|
October 30, 2025
|
|
EMA has updated its AI limits on 01 Aug 2025
|
|
17
|
2455
|
October 28, 2025
|
|
Nitrocellulose-Based Packaging Inks and Nitrosamine Risk
|
|
0
|
283
|
October 28, 2025
|
|
Determination of N-nitroso desmethyl Tetracycline
|
|
17
|
1026
|
October 27, 2025
|
|
🖥 Nitrosamines risk from Water for Pharmaceutical Purpose according to USP
|
|
2
|
863
|
October 24, 2025
|
|
IPEC Excipient new questionnaire, October 2025
|
|
2
|
212
|
October 23, 2025
|
|
N-Nitroso Sertraline
|
|
9
|
870
|
October 23, 2025
|
|
Updated: IPEC Questionnaire for Excipient Nitrosamines Risk Evaluation
|
|
2
|
492
|
October 23, 2025
|
|
Computational mechanistic study on N-nitrosation reaction of secondary amines-New pub
|
|
2
|
455
|
October 21, 2025
|
|
Guidelines for Antibiotic group drug substances for the limit of Nitrosamine impurities . (Eg. Azithromycin, Erythromycin )
|
|
5
|
1939
|
October 20, 2025
|
|
Carbazole reaction with nitrites
|
|
6
|
304
|
October 17, 2025
|
|
N-Nitrosamine Quantitation in Pharmaceuticals by Tandem Mass Spectrometry
|
|
1
|
282
|
October 16, 2025
|
|
Peptide Synthesis - Does anyone have experience with potential Nitrosamine impurities coming from solid phase synthesis?
|
|
1
|
190
|
October 16, 2025
|
|
N-Nitroso mirabegron
|
|
7
|
2682
|
October 15, 2025
|
|
Understanding nitrosamine risk in listed medicines
|
|
2
|
349
|
October 14, 2025
|
|
Help/Information needed: Are bis-Aryl-Azoxy-compounds CoC or not?
|
|
3
|
162
|
October 13, 2025
|
|
Chat GPT's answer about the risk assessment of nitrosamine in pharmaceuticals
|
|
32
|
3771
|
October 13, 2025
|
|
Should we test presence of Amine/ Chloramine in Potable Water and Nitrosamine in Purified Water?
|
|
0
|
155
|
October 13, 2025
|
|
Advancing Generic Drug Development: Translating Science to Approval 2025
|
|
3
|
428
|
October 10, 2025
|
|
Sample Prep for Complex Matrices - creams etc?
|
|
1
|
170
|
October 10, 2025
|
|
LTL Approach for New Generic Registrations
|
|
5
|
428
|
October 10, 2025
|
|
EMA Q&A Rev. 22 (EMA/409815/2020 Rev.22)
|
|
5
|
1999
|
October 10, 2025
|
|
Method Validation
|
|
3
|
164
|
October 8, 2025
|
|
Summary of Nitrosamines Exchange by ChatGPT (October 2025)
|
|
4
|
472
|
October 7, 2025
|
|
Nitrosamines without published AI, and possibly negative for carcinogenicity
|
|
11
|
1278
|
October 7, 2025
|
|
🇺🇸 US FDA- Generic Drug Science and Research Priority Initiatives for Fiscal Year (FY) 2026
|
|
0
|
234
|
October 6, 2025
|
|
🇺🇸 FDA Control of Nitrosamine Impurities in Human Drugs revision2
|
|
65
|
5889
|
October 3, 2025
|
|
🇲🇽 Mexico Nitrosamine Guide published today
|
|
44
|
3262
|
October 3, 2025
|
|
Use of recovery factor in nitrosamine analysis in drug product
|
|
4
|
336
|
October 3, 2025
|
|
US FDA- Generic Drug Science and Research Priority Initiatives for Fiscal Year (FY) 2024
|
|
2
|
603
|
October 1, 2025
|